Coverage
Filings
| Filing | Date |
|---|---|
| Novo Nordisk, insiders' tradings | 11 Nov 2005 |
| Novo Nordisk, insiders' tradings | 31 Oct 2005 |
| Novo Nordisk, quarterly report Q3 | 27 Oct 2005 |
| Novo Nordisk, insiders' tradings | 19 Oct 2005 |
| Novo Nordisk, announcement - own shares | 4 Oct 2005 |
| Novo Nordisk, insiders' tradings | 17 Aug 2005 |
| Novo Nordisk, insiders' tradings | 15 Aug 2005 |
| Novo Nordisk, interim report - six months | 11 Aug 2005 |
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 4 Jul 2005 |
| Novo Nordisk, receives US approval of Levemir® | 17 Jun 2005 |
| Novo Nordisk, notification from major shareholder (section 29) from Fidelity Investments | 26 May 2005 |
| Novo Nordisk, Novo Nordisk A/S purchases B shares worth DKK 646 million from Novo A/S | 17 May 2005 |